Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518.59 (market cap $40.43B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.32 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is the larger of the two by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 7,532,796). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| IDXX | VCIT | |
|---|---|---|
Market Cap | $40.43B | $72.20B |
Volume | 692,164 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $84.82 |
52-Week Low | $504.70 | $77.98 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
VCIT trades at $78.345 with minimal daily movement (+0.1%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against peers. However, bearish technical signals and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors in current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
